验证数据展示
经过测试的应用
Positive IHC detected in | human kidney tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF/ICC detected in | PC-3 cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
12518-1-AP targets MAP17 / PDZK1IP1 in IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
经测试应用 | IHC, IF/ICC, ELISA Application Description |
经测试反应性 | human |
免疫原 | MAP17 / PDZK1IP1 fusion protein Ag3206 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | PDZK1 interacting protein 1 |
别名 | Protein DD96, PDZK1IP1, PDZK1-interacting protein 1, MAP17, 17 kDa membrane-associated protein |
计算分子量 | 114 aa, 12 kDa |
GenBank蛋白编号 | BC012303 |
基因名称 | MAP17 |
Gene ID (NCBI) | 10158 |
RRID | AB_3085395 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity purification |
UNIPROT ID | Q13113 |
储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
PDZK1-interacting protein 1(PDZK1IP1), also known as MAP17, is a membrane-associated protein. MAP17 / PDZK1IP1 is overexpressed in a variety of human carcinomas, and overexpression of MAP17 / PDZK1IP1 protein is strongly correlated with the progression of prostate and ovarian carcinomas (PMID: 17426052). MAP17 / PDZK1IP1 has been proven to be an oncogene for tumorigenesis and development of papillary thyroid cancer (PTC) (PMID: 36057192; PMID: 35727731).
实验方案
Product Specific Protocols | |
---|---|
IHC protocol for MAP17 / PDZK1IP1 antibody 12518-1-AP | Download protocol |
IF protocol for MAP17 / PDZK1IP1 antibody 12518-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |